<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hornslien, A. G.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Long-Term Benefit of Candesartan for Patients with Acute Stroke</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Elevated blood pressure (BP) in the acute phase of stroke has been associated with poor short- and long-term outcomes [Leonard-Bee J et al. Stroke 2002]. The Scandinavian Candesartan Acute Stroke Trial [SCAST; NCT00120003] did not demonstrate a difference at 6 months between BP lowering with candesartan and placebo for 7 days in the acute phase of stroke (HR, 1.09; 95% CI, 0.84 to 1.41; p=0.52) [Sandset EC et al. Lancet 2011]. The aim of this SCAST prespecified secondary analysis was to investigate whether a difference might be observed over longer follow-up.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>